# Tao Capital

> Tao Capital is a VC fund in Beijing backing Health Care, Biotechnology and Medical. See 29 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 29
- Last investment: Jun 2026
- Lead investor: 31%
- Last updated: Aug 2026

Tao Capital is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 12 | 41% |
| Biotechnology | 11 | 38% |
| Medical | 7 | 24% |
| Pharmaceutical | 7 | 24% |
| Biopharma | 6 | 21% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 12 | 41% |
| Series B | 7 | 24% |
| Seed | 4 | 14% |
| Series C | 4 | 14% |
| Angel | 1 | 3% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 23 | 79% |
| United States | 3 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BCI-Sonics | BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications. | $14.8M | Angel | Jun 08, 2026 |  |
| TOPI Imaging Technology | TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer. | $57.9M | Venture - Series Unknown | Mar 26, 2026 |  |
| Xianyan Biopharma | Xianyan Biopharma is a company that focuses on core technology innovation and new medication development for oligonucleotides, and it has a top-tier R&D staff. | $21.8M | Series A | Mar 20, 2026 |  |
| Anaerobic Biotechnology | Anaerobic Biology is a domestic leader in the study and development of human microorganisms and has been heavily involved in the study and development of human intestine and vaginal flora. |  | Series A | Jan 26, 2026 |  |
| Ona Regenerative Medicine | Ona Regenerative Medicine is a biotechnology developer specializing in chemical products, focusing on creating innovative solutions that support tissue repair, regeneration, and overall biomedical advancement. |  | Seed | Nov 13, 2025 |  |
| Hyperway Pharm | Hyperway Pharm is a pharmaceutical R&D and production enterprise with R&D as the core driving force. It adheres to the philosophy of “Hai Na Baichuan, Bocai, Changzhi, Good People, and Great Deeds”, and is committed to building a world-leading research and development platform for small molecule innovative drugs and high-end APIs. Researchand development platform for research and development platforms and high-tech barriers. Its core founding team is a special high-end talent in Chengdu, Sichuan Province, and has many Fortune 500 companies such as Bayer, Johnson & Johnson, Sanofi and Merck, as well as “Kingming Kant”. Work experience of domestic well-known pharmaceutical companies such as “Hengrui”, “Yangzijiang”, “Hai Cisco”, “Smart Chemical” and “Bite Pharmaceutical”, with rich experience in international and domestic drug development and management, and led the team. It has successively developed a number of world-class innovative drugs (which have entered clinical trials) and a number of high-end high-end generic drugs | $28.1M | Series B | Oct 22, 2025 |  |
| Huanxin Medical | Huanxin Medical is an innovative medical device company that specializes in the research and development of interventional medical devices. |  | Series B | Aug 14, 2025 |  |
| Aoda Biotechnology | Aoda Biotechnology is a biopharmaceutical company. | $4.2M | Series A | Aug 11, 2025 |  |
| Tianzhuang Nutrition | Tianzhuang Nutrition is an innovative modern enterprise dedicated to the research, development, production, and sales of medical nutritional foods. |  | Series A | Jul 31, 2025 |  |
| Challenge IM | Challenge IM focuses on the development and application of membrane filtration process products in the biopharmaceutical field. |  | Seed | Oct 10, 2024 |  |

10 of 29 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [Fortune Venture Capital](https://shizune.co/investors/profile/fortune-venture-capital) — VC Fund, 3 deals together
- [Chengdu Science and Technology Venture Capital](https://shizune.co/investors/profile/chengdu-science-and-technology-venture-capital-group) — VC Fund, 2 deals together
- [CITIC Securities](https://shizune.co/investors/profile/citic-securities) — VC Fund, 2 deals together
- [Frees Fund](https://shizune.co/investors/profile/freesfund) — VC Fund, 2 deals together
- [GSR United Capital](https://shizune.co/investors/profile/gsr-united-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Medical Device VC Funds in China](https://shizune.co/investors/medical-device-vc-funds-china)

## FAQ

### What does Tao Capital invest in?

Tao Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 29 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tao Capital last invest?

The most recent investment recorded for Tao Capital closed in Jun 2026. Shizune tracks 29 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co